ANDA 85421, held by Pharmeral. Hydrochlorothiazide; Reserpine.
As of Nov 21, 2026, ANDA 85421 (Hydrochlorothiazide W/ Reserpine), held by Pharmeral, was first approved by FDA on Mar 17, 1977, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 17, 1977 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydrochlorothiazide W/ Reserpine25MG;0.125MG · tablet;oral | Hydrochlorothiazide; Reserpine | Discontinued |
| Jan 22, 1982 | Supplement 21Manufacturing | Approved | None posted |
| Jan 22, 1982 | Supplement 22Manufacturing | Approved | None posted |
| Mar 17, 1977 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters